Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose-escalation study of intravenous AMB-05X in tenosynovial giant cell tumor
NL-OMON50912Phase 2Not yet recruiting
- Sponsor
- AmMax Bio
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABM-05X in tenosynovial giant cell tumor (TGCT), sponsored by AmMax Bio. Primary endpoint: Frequency and severity of treatment-emergent adverse events. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
ABM-05X
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON50912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50912.